Everything below concerns Synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-03. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Most displays are rather simple and involve some type of song. Some displays, however, are quite elaborate. Depending on the species, these may include wing or tail drumming, dancing, aerial flights, or communal lekking. Females are generally the ones that drive partner selection, although in the polyandrous phalaropes, this is reversed: plainer males choose brightly coloured females. Courtship feeding, billing and allopreening are commonly performed between partners, generally after the birds have paired and mated. Homosexual behaviour has been observed in males or females in numerous species of birds, including copulation, pair-bonding, and joint parenting of chicks. Over 130 avian species around the world engage in sexual interactions between the same sex or homosexual behaviours. "Same-sex courtship activities may involve elaborate displays, synchronised dances, gift-giving ceremonies, or behaviours at specific display areas including bowers, arenas, or leks."
A diphenylamine (DPA) indicator will confirm the presence of DNA. This procedure involves chemical hydrolysis of DNA: when heated (e.g. ≥95 °C) in acid, the reaction requires a deoxyribose sugar and therefore is specific for DNA. Under these conditions, the 2-deoxyribose is converted to w-hydroxylevulinyl aldehyde, which reacts with the compound, diphenylamine, to produce a blue-colored compound. DNA concentration can be determined by measuring the intensity of absorbance of the solution at the 600 nm with a spectrophotometer and comparing to a standard curve of known DNA concentrations. Measuring the intensity of absorbance of the DNA solution at wavelengths 260 nm and 280 nm is used as a measure of DNA purity. DNA can be quantified by cutting the DNA with a restriction enzyme, running it on an agarose gel, staining with ethidium bromide (EtBr) or a different stain and comparing the intensity of the DNA with a DNA marker of known concentration. Using the Southern blot technique, this quantified DNA can be isolated and examined further using PCR and RFLP analysis. These procedures allow differentiation of the repeated sequences within the genome. It is these techniques which forensic scientists use for comparison, identification, and analysis.
primary The simplest, most commonly known, or canonical form of a chemical compound with multiple similar or isomeric forms. For example, in a primary alcohol, the carbon is bonded to a single substituent group (R1CH2OH), whereas a secondary alcohol is doubly substituted (R1R2CHOH) and a tertiary alcohol is triply substituted (R1R2R3COH).
The Rocky Mountains, west of the Great Plains, extend north to south across the country, peaking at over 14,000 feet (4,300 m) in Colorado. The supervolcano underlying Yellowstone National Park in the Rocky Mountains, the Yellowstone Caldera, is the continent's largest volcanic feature. Farther west are the rocky Great Basin and the Chihuahuan, Sonoran, and Mojave deserts. In the northwest corner of Arizona, carved by the Colorado River, is the Grand Canyon, a steep-sided canyon and popular tourist destination known for its overwhelming visual size and intricate, colorful landscape. The Cascade and Sierra Nevada mountain ranges run close to the Pacific coast. The lowest and highest points in the contiguous United States are in the state of California, about 84 miles (135 km) apart. Alaska is a state in the northwestern regions of North America. It is a semi-exclave and separated from the contiguous United States. At an elevation of 20,310 feet (6,190.5 m), Alaska's Denali (also called Mount McKinley) is the highest peak in the country and on the continent. Active volcanoes in the U.S. are common throughout Alaska's Alexander and Aleutian Islands, while Hawaii has six active volcanoes, including Kilauea and Mauna Loa. Located entirely outside North America, the Hawaiian archipelago consists of volcanic islands, all physiographically and ethnologically part of the Polynesian subregion of Oceania.
Sources: en.wikipedia.org
== Research and career == In the 1980s, Mojsov moved to the Massachusetts General Hospital (MGH) where she was made head of a peptide synthesis facility. She arrived at MGH shortly after Joel Habener had cloned proglucagon by studying anglerfish found in Boston Harbor. Mojsov worked on the identification of glucagon-like peptide-1 (GLP-1), a hormone generated by the gut that triggers the release of insulin. The amino acid sequence of GLP-1 was similar to a gastric inhibitory peptide, an incretin. To try to identify whether a specific fragment of GLP-1 was an incretin, Mojsov synthesized an incretin-antibody and developed ways to track its presence. Specifically, Mojsov identified that a stretch of 31 amino acids in the GLP-1 was an incretin. Together with Gordon Weir at the Joslin Diabetes Center in Boston and Habener, Mojsov showed that physiologic concentration of 5 × 10−11 of lab-synthesized GLP-1 could trigger insulin. All other reports at that time were for much higher concentrations thus not meeting Cretuzfeld's requirement that an incretin "must stimulate insulin secretion in a glucose-dependent manner at physiological levels". In the 1990s, Mojsov returned to New York City, where she went back to Rockefeller University and the laboratory of Ralph M. Steinman (2011 Nobel Prize in Physiology or Medicine). In 1992, the group at Massachusetts General Hospital (MGH) using GLP-1 synthesized by Mojsov tested the GLP-1 in humans. Drugs that emulate the action of GLP-1 have been developed into treatments for obesity and diabetes by Novo Nordisk and Eli Lilly.
The symptoms of PSSD are largely shared with post-finasteride syndrome and post-retinoid sexual dysfunction, two other poorly understood conditions which have been suggested to share a common etiology with PSSD despite being associated with different types of medication. Diagnostic criteria for PSSD were proposed in 2022, but as of 2023, there is no agreement on standards for diagnosis. It is a distinct phenomenon from antidepressant discontinuation syndrome, post-acute withdrawal syndrome, and major depressive disorder, and should be distinguished from sexual dysfunction associated with depression and persistent genital arousal disorder. There are limited treatment options for PSSD as of 2023 and no evidence that any individual approach is effective. The mechanism by which SSRIs may induce PSSD is unclear. However, various neurochemical, hormonal, and biochemical changes during SSRI use—such as reduced dopamine levels, increased serotonin, inhibition of nitric oxide synthase, and the blocking of cholinergic and alpha-1 adrenergic receptors—could account for their sexual adverse effects. Additionally, SSRIs may cause peripheral changes by inhibiting serotonin receptors in peripheral nerves, which may also play a role in PSSD. As of 2023, prevalence is unknown. A 2020 review stated that PSSD is rare, underreported, and "increasingly identified in online communities". A 19 year retrospective analysis looking at people with erectile dysfunction who met most of the criteria for PSSD found that the estimated risk was 0.46%.
A 2021 poll by WR Numero Research revealed that 54.59% of voters want soft continuity of Duterte's policies, 29.57% want full continuity, while only 15.84% preferred change. Duterte left office with a net satisfaction rating of 81%, his highest in SWS polling. Additionally, polling firm PUBLiCUS Asia reported in Duterte's last month in office that Duterte received a 75% approval for his entire six-year tenure, making him the most popular post-EDSA president.
== Risk factors == The increase in obesity in Brazil has been associated with multiple factors, including increased consumption of ultra-processed foods, reduced levels of physical activity, urbanisation and lifestyle changes, socioeconomic inequalities, increased sedentary behaviour, and changes in transportation and occupational patterns. Research has demonstrated associations between obesity and age, educational attainment, income, and regional disparities. Brazil's nutrition transition has been characterised by a gradual shift from traditional dietary patterns toward increased consumption of processed and ultra-processed foods.
== Stability == Avobenzone is sensitive to the properties of the solvent, being relatively stable in polar protic solvents and unstable in nonpolar environments. Also, when it is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or it can transfer energy to biological targets and cause deleterious effects. Avobenzone has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. Data presented to the Food and Drug Administration by the Cosmetic, Toiletry and Fragrance Association indicates a −36% change in avobenzone's UV absorbance following one hour of exposure to sunlight. For this reason, in sunscreen products, avobenzone is always formulated together with a photostabilizer, such as octocrylene. Other photostabilizers include:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.